Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Sabrina L Browning, MD, Terri L Parker, MD, Noffar Bar, MD, Stuart Seropian, MD, Alfred I Lee, MD PhD, Tara Anderson, PA, Natalia Neparidze, MD

Blood (2019) 134 (Supplement_1): 5569.

https://doi.org/10.1182/blood-2019-130134

Published: 2019

Journal Articles

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Ramon Cruz, Salli Fennessey, Anthony C Shelton, RN

Blood (2018) 132 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2018-99-112991

Published: 2018

Journal Articles

Pegylated E. coli Asparaginase Desensitization: An Effective and Feasible Option for Pediatric Patients with Acute Lymphoblastic Leukemia Who Have Developed Hypersensitivity to Pegaspargase in the Absence of Asparaginase Erwinia Chrysanthemi availability

Anupam Verma, MD, Karin Chen, MD, Jacob Johnsen, PharmD, Phillip Barnette, MD

Blood (2018) 132 (Supplement 1): 5205.

https://doi.org/10.1182/blood-2018-99-119866

Published: 2018

Journal Articles

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Issam S. Hamadeh, PharmD, Justin Arnall, Pharm.D., Ekaterina Kachur, PharmD, Allison Martin, PharmD, Megan Helena Jagosky, MD, Reed Friend, MD, Shebli Atrash, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2018-99-118737

Published: 2018

Journal Articles

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Ajai Chari, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Hareth Nahi, MD PhD, Jie Tang, Peter Hellemans, Brenda Tromp, MSc, Pamela L Clemens, PhD, Andrew Farnsworth, Jesus F San-Miguel, MD PhD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2018-99-113590

Published: 2018

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi, MD, Asad Bashey, MD PhD, James M. Foran, MD, Wendy Stock, MD, Raya Mawad, MD, William Blum, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, K. Gary J. Vanasse, MD, Thomas Ly, PhD, Hagop M. Kantarjian, MD, Bhavana Bhatnagar, DO, Koichi Takahashi, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 763.

https://doi.org/10.1182/blood-2018-99-119786

Published: 2018

Journal Articles

Re-Presentation to Medical Care Due to Adverse Effects of Intravenous Immunoglobulin Therapy in Pediatric Immune Thrombocytopenia Patients

Amanda Grimes, MD, Taylor Olmsted, MD, Susan E. Kirk, PA-C, Michele P. Lambert, MD, Jenny M. Despotovic, DO, MS

Blood (2017) 130 (Supplement 1): 3413.

https://doi.org/10.1182/blood.V130.Suppl_1.3413.3413

Published: 2017

Journal Articles

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, William I. Bensinger, MD, John M Burke, MD, Sriya Gunawardena, MD, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, PhD, Anil Londhe, PhD, Ming Qi, Jon Ukropec, Thomas Lin, Robert M. Rifkin, MD

Blood (2017) 130 (Supplement 1): 1839.

https://doi.org/10.1182/blood.V130.Suppl_1.1839.1839

Published: 2017

Journal Articles

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Salli Fennessey, Anthony C Shelton, RN

Blood (2017) 130 (Supplement 1): 507.

https://doi.org/10.1182/blood.V130.Suppl_1.507.507

Published: 2017

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Rapid Infusion of Rituximab Is Well Tolerated in Children with Hematologic, Oncologic, and Rheumatologic Disorders

Amanda Bell Grimes, MD, Marietta M DeGuzman, MD, Jessica Poehls, PharmD, Taylor Olmsted, MD, Rachel Beaty Carroll, PharmD, Michele S Redell, MD PhD, Susan E. Kirk, PA-C, Charles G Minard, PhD, Melanie Brooke Bernhardt, PharmD, MS, Jenny M. Despotovic, DO, MS

Blood (2016) 128 (22): 2329.

https://doi.org/10.1182/blood.V128.22.2329.2329

Published: 2016

Journal Articles

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Dale Bixby, MD PhD, Matthew J. Wieduwilt, MD PhD, Luke Paul Akard, MD, H. Jean Khoury, MD, Pamela S. Becker, MD PhD, Edward H. Van Der Horst, PhD, William Ho, MD PhD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3809.

https://doi.org/10.1182/blood.V126.23.3809.3809

Published: 2015

Journal Articles

Red Blood Cell Depletion for Pediatric Major ABO Mismatch BMT: Evaluation of the Risk of Hemolysis and Comparison of Two Techniques

Robert Sheppard Nickel, MD MSc, Ashley Dulson, Diana Worthington-White, MD, Muna Qayed, MD MSc, Kuang-Yueh Chiang, MD PhD

Blood (2015) 126 (23): 3096.

https://doi.org/10.1182/blood.V126.23.3096.3096

Published: 2015

Journal Articles

Combination Of Ofatumumab and Bortezomib In Patients With Indolent B-Cell Lymphomas Who Relapsed >6 Months After Rituximab-Containing Regimen: A Brown University Oncology Research Group Phase II Study

Jorge J Castillo, MD, James N Butera, MD, Eric S Winer, MD, Frederick Lansigan, MD, Kayla Rosati, Howard Safran, MD

Blood (2013) 122 (21): 5121.

https://doi.org/10.1182/blood.V122.21.5121.5121

Published: 2013

Journal Articles

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma

Ajay K. Gopal, MD, Stefano R Tarantolo, Naresh Bellam, MD, MPH, Tatyana Feldman, MD, Anthony R Mato, MD, Damian J Green, MD, Melissa Griffin, Scott Stromatt, MD, Andre Goy, MD

Blood (2012) 120 (21): 3678.

https://doi.org/10.1182/blood.V120.21.3678.3678

Published: 2012

Journal Articles

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

Beth Christian, MD, Lapo Alinari, MD., Ph.D., Jeffrey A. Jones, MD, MPH, Don M Benson, Jr., MD, PhD, Joseph M. Flynn, DO, MPH, Pierluigi Porcu, MD, Mark E Lustberg, MD, PhD, Mitchell Phelps, Ph.D., Ming Poi, PharmD, PhD, Diana Chung, BS, Carl Quinion, John C. Byrd, MD, William Wegener, MD, PhD, David M Goldenberg, Robert A. Baiocchi, M.D., Ph.D., Kristie A. Blum, MD

Blood (2011) 118 (21): 3707.

https://doi.org/10.1182/blood.V118.21.3707.3707

Published: 2011

Journal Articles

3G8 and GMA161, Anti FcγRIII Inhibitory Monoclonal Antibodies in the Treatment of Chronic Refractory ITP. (Summary of 2 Pilot Studies).

Charles T Nakar, MD, James B. Bussel, MD

Blood (2009) 114 (22): 2404.

https://doi.org/10.1182/blood.V114.22.2404.2404

Published: 2009

Journal Articles

Comparison of Intravenous Immune Globulin and High Dose Anti-D Immune Globulin as Initial Therapy for Childhood Immune Thrombocytopenic Purpura.

Ian Kane, B.S., Dominic Ragucci, PharmD, Ibrahim Shatat, MD, MSCR, Ram Kalpatthi, MD

Blood (2008) 112 (11): 3434.

https://doi.org/10.1182/blood.V112.11.3434.3434

Published: 2008

Journal Articles

Efficacy and Safety of a New Intravenous Immunoglobulin Product in Patients with Chronic Immune Thrombocytopenic Purpura.

Tadeusz Robak, Abdulgabar Salama, Lidia Kovaleva, Yaroslava I. Vyhovska, Simon Davies, Maria G. Mazzucconi, Othmar Zenker

Blood (2007) 110 (11): 1307.

https://doi.org/10.1182/blood.V110.11.1307.1307

Published: 2007

NARROW

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Pegylated E. coli Asparaginase Desensitization: An Effective and Feasible Option for Pediatric Patients with Acute Lymphoblastic Leukemia Who Have Developed Hypersensitivity to Pegaspargase in the Absence of Asparaginase Erwinia Chrysanthemi availability

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Re-Presentation to Medical Care Due to Adverse Effects of Intravenous Immunoglobulin Therapy in Pediatric Immune Thrombocytopenia Patients

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Rapid Infusion of Rituximab Is Well Tolerated in Children with Hematologic, Oncologic, and Rheumatologic Disorders

A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Red Blood Cell Depletion for Pediatric Major ABO Mismatch BMT: Evaluation of the Risk of Hemolysis and Comparison of Two Techniques

Combination Of Ofatumumab and Bortezomib In Patients With Indolent B-Cell Lymphomas Who Relapsed >6 Months After Rituximab-Containing Regimen: A Brown University Oncology Research Group Phase II Study

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Rituximab and Bendamustine in Relapsed Indolent Lymphoma

Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,

3G8 and GMA161, Anti FcγRIII Inhibitory Monoclonal Antibodies in the Treatment of Chronic Refractory ITP. (Summary of 2 Pilot Studies).

Comparison of Intravenous Immune Globulin and High Dose Anti-D Immune Globulin as Initial Therapy for Childhood Immune Thrombocytopenic Purpura.

Efficacy and Safety of a New Intravenous Immunoglobulin Product in Patients with Chronic Immune Thrombocytopenic Purpura.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only